According to a recent report, the global cell culture market is projected to increase at a CAGR of 10.5% over the next five years.
This growth will be driven by the increasing prevalence of chronic diseases, a growing number of regulatory approvals for cell culture-base vaccines, a demand for mAbs, new funding for cell-based research, and a rising adoption of single-use technologies. Additionally, technological advancements in cell culture products will also contribute greatly.
Yet, growth won’t come without its challenges, specifically the high cost of research in cell biology and the lack of infrastructure for cell-based research, which could both impede growth during the projected period.
Regionally, the highest growth rate will be seen in Asia, as it become as preferred destination due to its significantly lower production costs.
“Moreover, regulatory norms in these countries are less stringent and the cost of labor is less. This in turn reduces the cost of production of biologics,” the report added.
“Owing to these benefits, various pharmaceutical giants are actively investing in these markets to develop biopharmaceutical drugs.”
For example, Boehringer Ingelheim invested €35m ($46.4m) in June 2013 to establish a cGMP biopharmaceutical manufacturing facility in China.
The reporting company also released a global cell analysis market forecast, in which it projects the market will reach $26bn by 2020 from $19bn in 2015, growing at a CAGR of 6.56% from 2015 to 2020.
According to this report, single cell analysis and qPCR in the Asia-Pacific region are expected to bring in new revenue for the cell analysis market in the next five years.